Berdagang MerckCo USA MRK

MerckCo carta live

Asas Instrumen

Weekly Search
Weekly
Daily
Tarikh Tutup Perubahan Perubahan (%): Buka Tinggi Rendah

MerckCo news

Big Tech, Apple, Meta, Microsoft, Amazon & Alphabet
Neil Wilson 2024 Oct 24, 16:00

Week ahead: Apple leads big tech earnings, UK Budget and Nonfarm Payrolls

Forex Indices
Bank of England, BoJ, Fed all hold policy meetings this week
Georgy Istigechev 2024 Jul 25, 16:00

Week ahead: Eurozone inflation, Fed meeting, Apple earnings

Forex Indices
Magnificent Seven earnings take centre stage in the markets this week
Neil Wilson 2024 Apr 19, 01:00

Week ahead: Wall Street’s Magnificent Seven earnings are up

Commodities Forex Indices Shares
The Bank of England
Neil Wilson 2024 Jan 25, 08:03

Week ahead: Fed, BoE to hold; Apple leads big tech earnings

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares

Berita Terkini

Tunjukkan lebih lagi
Noah Lee 2025 Aug 27, 09:20

Asian Markets Ease Gold ETF Restrictions Amid Geopolitical Uncertainty

Ava Grace 2025 Aug 27, 08:20

Russia's Economic Dilemma: Will the Ukraine War Push Towards Peace?

Ava Grace 2025 Aug 27, 07:20

Goldman Sachs Predicts Oil Prices to Plunge to $50s by 2026: Analyzing the Forecast

Noah Lee 2025 Aug 27, 06:20

Cryptocurrency in Venezuela: An Economic Lifeline Amidst Hyperinflation and Sanctions

Liam James 2025 Aug 27, 06:20

Cambricon Shares Surge Amidst AI Chip Demand

Emma Rose 2025 Aug 27, 05:20

US Tariffs on India: Economic Impact and Analysis

Liam James 2025 Aug 27, 03:20

Iran Nuclear Deal Talks Stall: UN Sanctions Revival Looms

Emma Rose 2025 Aug 27, 03:20

ExxonMobil Rethinks Sakhalin: A Potential Return Amid Geopolitical Shifts

Maklumat

Sebaran nilai

0.53

Spread (%)

0.6245 %

Leveraj

1:10

Faedah semalaman (Beli)

-0.0597 %

Faedah semalaman (Jual)

-0.0292 %

Mata wang

USD

Waktu perdagangan

Pasaran ditutup

Rabu

13:31 - 19:59

Isnin

13:31-19:59

Selasa

13:31-19:59

Khamis

13:31-19:59

Jumaat

13:31-19:59

Analisis dan statistik

Buka

---

Tutup Terdahulu

---

Tinggi/Rendah 52 Minggu

--- – ---

Modal pasaran

213085601792

Saham Tertunggak

2497779968

Tarikh Pendapatan (Seterusnya)

2021-06-03

Hasil Div

2025-10-07

Tarikh Selepas Dividen

2025-09-15

Kadar dividen tahunan depan

3.24

Hasil dividen tahunan depan

0.0371

EPS

6.49

Ketahui lebih lanjut mengenai instrumen ini

MerckCo USA Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and ant

latest_education_articles

Tunjukkan lebih lagi
Trustpilot